博士毕业于中国科学院上海生命科学研究院,之后赴美国肯塔基大学Markey癌症中心进行博士后研究,2015年起在南方医科大学担任教授,博士生导师。长期从事乳腺癌演进与耐药机制的研究,以通讯作者或第一作者身份在Cancer Cell, Nature Communications和Theranostics等国际著名期刊发表研究论文,揭示了三阴乳腺癌的潜在药物治疗靶点Twist/BRD4复合体(Cancer Cell, 2014),阐明了FOXO3a/BRD4复合体在乳腺癌细胞对AKT抑制剂药物抵抗中的重要作用(Nature Communications,2018),并发现JunD/RSK3信号途径调控乳腺癌细胞对BET抑制剂的药物敏感性(Nature Communications,2020)。主持国基金面上项目四项。
Enhanced JunD/RSK3 signalling due to loss of BRD4/FOXD3/miR-548d-3p axis determines BET inhibition resistance.
Tai F, Gong K, Song K, He Y, Shi J. Nat Commun. 2020 Jan 14;11(1):258.
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
Liu J, Duan Z, Guo W, Zeng L, Wu Y, Chen Y, Tai F, Wang Y, Lin Y, Zhang Q, He Y, Deng J, Stewart RL, Wang C, Lin PC, Ghaffari S, Evers BM, Liu S, Zhou MM, Zhou BP, Shi J. Nat Commun. 2018 Dec 5;9(1):5200.
Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer
Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang Q, Lin Y, Li J, Kang T, Tao M, Rusinova E, Zhang G, Wang C, Zhu H, Yao J, Zeng YX, Evers BM, Zhou MM, Zhou BP. Cancer Cell. 2014 Feb 10;25(2):210-25.